Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Spero Therapeutics (SPRO) Invested Capital (2016 - 2025)

Historic Invested Capital for Spero Therapeutics (SPRO) over the last 10 years, with Q3 2025 value amounting to $26.5 million.

  • Spero Therapeutics' Invested Capital fell 5955.55% to $26.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.5 million, marking a year-over-year decrease of 5955.55%. This contributed to the annual value of $46.1 million for FY2024, which is 5685.16% down from last year.
  • Latest data reveals that Spero Therapeutics reported Invested Capital of $26.5 million as of Q3 2025, which was down 5955.55% from $32.8 million recorded in Q2 2025.
  • Over the past 5 years, Spero Therapeutics' Invested Capital peaked at $118.8 million during Q1 2021, and registered a low of $26.5 million during Q3 2025.
  • Moreover, its 5-year median value for Invested Capital was $64.8 million (2023), whereas its average is $67.3 million.
  • Its Invested Capital has fluctuated over the past 5 years, first tumbled by 7084.32% in 2022, then skyrocketed by 6461.3% in 2023.
  • Quarter analysis of 5 years shows Spero Therapeutics' Invested Capital stood at $88.3 million in 2021, then fell by 13.99% to $75.9 million in 2022, then soared by 40.77% to $106.9 million in 2023, then plummeted by 56.85% to $46.1 million in 2024, then plummeted by 42.56% to $26.5 million in 2025.
  • Its Invested Capital stands at $26.5 million for Q3 2025, versus $32.8 million for Q2 2025 and $33.8 million for Q1 2025.